Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated utilizing the latest escalation factors available to Boeing on the date of this Purchase Agreement projected to the month of scheduled delivery.
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated using the 737-8 Airframe Price, average optional features price, and average SPE as of the date of this Purchase Agreement escalated at a rate of **** per year to the scheduled delivery year.
Advance Payment Base Prices. The Advance Payment Base Price and the Advance Payment Schedule for each Aircraft is listed in Table 1.
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated using the *** and *** as of the date of this Purchase Agreement escalated at a rate of *** percent (***%) per year to the scheduled delivery year.
Advance Payment Base Prices. The Advance Payment Base Prices listed in the applicable Table 1 [*CTR]
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated using the 737-8 Airframe Price and average optional features BOEING PROPRIETARY “[***]” This information is subject to confidential treatment and has been omitted and filed separately with the commission price as of the date of this Purchase Agreement escalated at a rate of three percent (3%) per year to the scheduled delivery year.
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated utilizing the latest escalation factors available to
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were calculated using the 737-8 [*CTR] BOEING PROPRIETARY [*CTR]
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were [ * ] to Boeing on the date of this Purchase Agreement projected to the month of scheduled delivery.
Advance Payment Base Prices. The Advance Payment Base Prices listed in Table 1 were [CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SEC PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT].
